Omega Therapeutics, Inc. (OMGA) Misses Q2 EPS by 4c
Omega Therapeutics, Inc. (NASDAQ: OMGA) reported Q2 EPS of ($0.54), $0.04 worse than the analyst estimate of ($0.50). Revenue for the quarter came in at $760 thousand versus the consensus estimate of $378.57 thousand.
For earnings history and earnings-related data on Omega Therapeutics, Inc. (OMGA) click here.
